3.5 Publications

July 27, 2021

A Pan-Cancer Organoid Platform for Precision Medicine

Cell Reports, Tempus-authored — Patient-derived tumor organoids (TOs) are emerging as high-fidelity models to study cancer biology and develop novel precision medicine therapeutics. However, utilizing TOs for systems-biology-based approaches has been limited by a lack of scalable and reproducible methods to develop and profile these models. We describe a r...

July 5, 2021

Somatic Tumor Profile Analysis in a Patient with Germline PMS2 Mutation and Synchronous Ovarian and Uterine Carcinomas

Journal of Personalized Medicine, Tempus-authored — Lynch syndrome patients with synchronous endometrial and ovarian cancer (SEOC) are rare. When these cases occur, they are most often endometrioid histology and early grade. Early-grade tumors are not often sent for somatic tumor profiling. We present a 39 year old SEOC patient with...

July 2, 2021

Validation of a Liquid Biopsy Assay With Molecular and Clinical Profiling of Circulating Tumor DNA

npj Precision Oncology, Tempus-authored — Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-invasive approach to identify biomarkers, detect resistance mutations, monitor disease burden, and identify early recurrence. The Tempus xF liquid biopsy assay is a 105-gene, hybrid-capture, next-generation sequencing (NGS) assay that d...

July 2, 2021

Deep Orthogonal Fusion: Multimodal Prognostic Biomarker Discovery Integrating Radiology, Pathology, Genomic, and Clinical Data

arXiv, Tempus-authored — Clinical decision-making in oncology involves multimodal data such as radiology scans, molecular profiling, histopathology slides, and clinical factors. Despite the importance of these modalities individually, no deep learning framework to date has combined them all to predict patient prognosis. Here, we predict the overall survival (OS...

June 10, 2021

Summary of the 12 Most Common Cancers in the CancerLinQ Discovery (CLQD) Database

JCO Clinical Cancer Informatics, Tempus-acknowledged — PURPOSE In 2014, the ASCO developed CancerLinQ (CLQ), a health technology platform for oncology. The CLQ Discovery (CLQD) database was created to make data available for research and this paper provides a summary of this database. METHODS This study described the clinical and demographic characteristics of the 12 most common cancers...

May 20, 2021

Characterizing Demographics, Clinical, and Genomic Characteristics for U.S. Patients With HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor.

ASCO Annual Meeting 2021, Tempus-acknowledged — Background: Cyclin-dependent kinases 4 and 6 inhibitors (CDK4 & 6i) have advanced the therapeutic landscape for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). However, there is an unmet need for treatment strategies following progression on CDK4 & 6i +/- endocr...

May 20, 2021

Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing

Nature Genetics in Medicine, Tempus-authored — 2021 Update: A Policy Statement of the American College of Medical Genetics and Genomics (ACMG) View the full publication here. Authors: David T. Miller, Kristy Lee, Adam S. Gordon, Laura M. Amendola, Kathy Adelman, Sherri J. Bale, Wendy K. Chung, Michael H. Gollob, Stev...

May 20, 2021

Comprehensive Genomic Profiling in Advanced/Metastatic Colorectal Cancer: Number Needed to Test and Budget Impact of Expanded First-line Use

ASCO Annual Meeting 2021, Tempus-authored — Background: A growing number of genomic alterations inform treatment of advanced/metastatic colorectal cancer (mCRC). However, use of comprehensive genomic profiling (CGP) is limited in the first-line (1L) setting. Based on the Tempus xT next-generation sequencing assay, we estimated the impact of expanded ...

May 20, 2021

Primary Pancreatic Adenocarcinoma (PPDA) and Metastatic Pancreatic Adenocarcinoma (MPDA): Are They Genomically Distinct?

ASCO Annual Meeting 2021, Tempus-authored — Background: PDA is an aggressive disease with a dismal prognosis. Advances in next-generation sequencing (NGS) have enabled targeted therapies, revolutionizing treatments of several solid tumors. Their role in the management of PDA is limited, in part due to the paucity in our understand...

May 20, 2021

Expanding the Molecular Taxonomy of NUT Midline Carcinomas With Multiomic Analyses

ASCO Annual Meeting 2021, Tempus-authored — Background: NUT midline carcinoma (NMC) is an aggressive squamous cell carcinoma molecularly defined by a chromosomal rearrangement of nuclear protein in testis (NUTM1) with bromodomain-containing protein 3 or 4 (BRD3/4). While NMCs are characterized by this rare canonical gene rearrangement little is known about the transc...

Show More